3 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 24 points (0.1%) at 16,720 as of Tuesday, May 13, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,382 issues advancing vs. 1,595 declining with 161 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Dr Reddy Laboratories ( RDY), down 5.5%, Biomarin Pharmaceutical ( BMRN), down 2.5% and Biogen Idec ( BIIB), down 1.3%. Top gainers within the industry include Eli Lilly and ( LLY), up 1.7%, Teva Pharmaceutical Industries ( TEVA), up 1.7%, Actavis ( ACT), up 1.4%, Allergan ( AGN), up 1.3% and Forest Laboratories ( FRX), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Vertex Pharmaceuticals is down $1.15 (-1.7%) to $66.59 on light volume. Thus far, 461,201 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $66.32-$67.93 after having opened the day at $67.62 as compared to the previous trading day's close of $67.74.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $15.4 billion and is part of the health care sector. Shares are down 8.8% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AbbVie ( ABBV) is down $0.29 (-0.6%) to $52.08 on light volume. Thus far, 2.1 million shares of AbbVie exchanged hands as compared to its average daily volume of 6.2 million shares. The stock has ranged in price between $51.92-$52.50 after having opened the day at $52.50 as compared to the previous trading day's close of $52.37.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $83.4 billion and is part of the health care sector. Shares are down 0.8% year-to-date as of the close of trading on Monday. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $7.18 (-2.5%) to $284.21 on light volume. Thus far, 432,599 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $283.50-$290.91 after having opened the day at $290.91 as compared to the previous trading day's close of $291.39.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $27.6 billion and is part of the health care sector. Shares are up 5.9% year-to-date as of the close of trading on Monday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing